Literature DB >> 30715177

Biallelic KARS pathogenic variants cause an early-onset progressive leukodystrophy.

Masayuki Itoh1, Hongmei Dai1, Shin-Ichi Horike2, John Gonzalez3, Yoshikazu Kitami1, Makiko Meguro-Horike2, Ichiro Kuki4, Shuichi Shimakawa5, Harumi Yoshinaga6, Yoko Ota7, Tetsuya Okazaki8, Yoshihiro Maegaki8, Shin Nabatame9, Shin Okazaki4, Hisashi Kawawaki4, Naoto Ueno10,11, Yu-Ichi Goto1, Yoichi Kato3,12.   

Abstract

The leukodystrophies cause severe neurodevelopmental defects from birth and follow an incurable and progressive course that often leads to premature death. It has recently been reported that abnormalities in aminoacyl t-RNA synthetase (ARS) genes are linked to various unique leukodystrophies and leukoencephalopathies. Aminoacyl t-RNA synthetase proteins are fundamentally known as the first enzymes of translation, catalysing the conjugation of amino acids to cognate tRNAs for protein synthesis. It is known that certain aminoacyl t-RNA synthetase have multiple non-canonical roles in both transcription and translation, and their disruption results in varied and complicated phenotypes. We clinically and genetically studied seven patients (six male and one female; aged 2 to 12 years) from five unrelated families who all showed the same phenotypes of severe developmental delay or arrest (7/7), hypotonia (6/7), deafness (7/7) and inability to speak (6/7). The subjects further developed intractable epilepsy (7/7) and nystagmus (6/6) with increasing age. They demonstrated characteristic laboratory data, including increased lactate and/or pyruvate levels (7/7), and imaging findings (7/7), including calcification and abnormal signals in the white matter and pathological involvement (2/2) of the corticospinal tracts. Through whole-exome sequencing, we discovered genetic abnormalities in lysyl-tRNA synthetase (KARS). All patients harboured the variant [c.1786C>T, p.Leu596Phe] KARS isoform 1 ([c.1702C>T, p.Leu568Phe] of KARS isoform 2) either in the homozygous state or compound heterozygous state with the following KARS variants, [c.879+1G>A; c.1786C>T, p.Glu252_Glu293del; p.Leu596Phe] ([c.795+1G>A; c.1702C>T, p.Glu224_Glu255del; p.Leu568Phe]) and [c.650G>A; c.1786C>T, p.Gly217Asp; p.Leu596Phe] ([c.566G>A; c.1702C>T, p.Gly189Asp; p.Leu568Phe]). Moreover, similarly disrupted lysyl-tRNA synthetase (LysRS) proteins showed reduced enzymatic activities and abnormal CNSs in Xenopus embryos. Additionally, LysRS acts as a non-canonical inducer of the immune response and has transcriptional activity. We speculated that the complex functions of the abnormal LysRS proteins led to the severe phenotypes in our patients. These KARS pathological variants are novel, including the variant [c.1786C>T; p.Leu596Phe] (c.1702C>T; p.Leu568Phe) shared by all patients in the homozygous or compound-heterozygous state. This common position may play an important role in the development of severe progressive leukodystrophy. Further research is warranted to further elucidate this relationship and to investigate how specific mutated LysRS proteins function to understand the broad spectrum of KARS-related diseases.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  calcification; development deterioration; intractable epilepsy; leukoencephalopathy; lysyl-tRNA synthetase gene (KARS)

Mesh:

Substances:

Year:  2019        PMID: 30715177     DOI: 10.1093/brain/awz001

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  6 in total

1.  Defects in aminoacyl-tRNA synthetase cause partial B and T cell immunodeficiency.

Authors:  Ju A Shim; Yuna Jo; Hyunju Hwang; So Eun Lee; Dahyeon Ha; Jun Hwa Lee; Jayoung Kim; Parkyong Song; Dongjun Lee; Changwan Hong
Journal:  Cell Mol Life Sci       Date:  2022-01-23       Impact factor: 9.261

2.  Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease.

Authors:  Gerarda Cappuccio; Camilla Ceccatelli Berti; Enrico Baruffini; Jennifer Sullivan; Vandana Shashi; Tamison Jewett; Tara Stamper; Silvia Maitz; Francesco Canonico; Anya Revah-Politi; Gabriel S Kupchik; Kwame Anyane-Yeboa; Vimla Aggarwal; Andreas Benneche; Eirik Bratland; Siren Berland; Felice D'Arco; Cesar A Alves; Adeline Vanderver; Daniela Longo; Enrico Bertini; Annalaura Torella; Vincenzo Nigro; Alessandra D'Amico; Marjo S van der Knaap; Paola Goffrini; Nicola Brunetti-Pierri
Journal:  Hum Mutat       Date:  2021-05-11       Impact factor: 4.700

3.  Progressive Early-Onset Leukodystrophy Related to Biallelic Variants in the KARS Gene: The First Case Described in Latin America.

Authors:  Adriana Vargas; Jorge Rojas; Ivan Aivasovsky; Sergio Vergara; Marianna Castellanos; Carolina Prieto; Luis Celis
Journal:  Genes (Basel)       Date:  2020-11-29       Impact factor: 4.096

4.  Leopard-like retinopathy and severe early-onset portal hypertension expand the phenotype of KARS1-related syndrome: a case report.

Authors:  Francesca Peluso; Viviana Palazzo; Giuseppe Indolfi; Francesco Mari; Roberta Pasqualetti; Elena Procopio; Claudia Nesti; Renzo Guerrini; Filippo Santorelli; Sabrina Giglio
Journal:  BMC Med Genomics       Date:  2021-01-21       Impact factor: 3.063

5.  Oligodendrocyte differentiation alters tRNA modifications and codon optimality-mediated mRNA decay.

Authors:  Sophie Martin; Kevin C Allan; Otis Pinkard; Thomas Sweet; Paul J Tesar; Jeff Coller
Journal:  Nat Commun       Date:  2022-08-25       Impact factor: 17.694

6.  Biallelic variants in KARS1 are associated with neurodevelopmental disorders and hearing loss recapitulated by the knockout zebrafish.

Authors:  Sheng-Jia Lin; Barbara Vona; Patricia G Barbalho; Rauan Kaiyrzhanov; Reza Maroofian; Cassidy Petree; Mariasavina Severino; Valentina Stanley; Pratishtha Varshney; Paulina Bahena; Fatema Alzahrani; Amal Alhashem; Alistair T Pagnamenta; Gudrun Aubertin; Juvianee I Estrada-Veras; Héctor Adrián Díaz Hernández; Neda Mazaheri; Andrea Oza; Jenny Thies; Deborah L Renaud; Sanmati Dugad; Jennifer McEvoy; Tipu Sultan; Lynn S Pais; Brahim Tabarki; Daniel Villalobos-Ramirez; Aboulfazl Rad; Hamid Galehdari; Farah Ashrafzadeh; Afsaneh Sahebzamani; Kolsoum Saeidi; Erin Torti; Houda Z Elloumi; Sara Mora; Timothy B Palculict; Hui Yang; Jonathan D Wren; Manali Joshi; Martine Behra; Shawn M Burgess; Swapan K Nath; Michael G Hanna; Margaret Kenna; J Lawrence Merritt; Henry Houlden; Ehsan Ghayoor Karimiani; Maha S Zaki; Thomas Haaf; Fowzan S Alkuraya; Joseph G Gleeson; Gaurav K Varshney
Journal:  Genet Med       Date:  2021-06-25       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.